IPG7236 / Immunophage Biotech - LARVOL DELTA

Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=196 | Recruiting | Sponsor: Nanjing Immunophage Biotech Co., Ltd | Phase classification: P1 ➔ P1/2

Phase classification • Melanoma • Oncology • Solid Tumor • Triple Negative Breast Cancer

AIMEFIE and Shanghai Gaobo Cancer Hospital jointly promote the Phase II clinical trial of IPG7236 [Google translation] (bydrug.pharmcube.com) - "AIMFIB Pharmaceuticals announced that it has reached a comprehensive strategic cooperation with Shanghai Gaobo Cancer Hospital affiliated to China Pharmaceutical University on IPG7236, the world's first small molecule antagonist targeting CCR8, which it independently developed. According to the agreement, Shanghai Gaobo Cancer Hospital will continue to promote the Phase II clinical trial of IPG7236 based on the existing clinical trials. Professor Li Jin, President, Chief Scientist and Chief Physician of Shanghai Gaobo Cancer Hospital affiliated to China Pharmaceutical University, will serve as the PI and be fully responsible for the Phase II clinical trial of IPG7236."

Licensing / partnership • Solid Tumor

Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=196 | Recruiting | Sponsor: Nanjing Immunophage Biotech Co., Ltd | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Sep 2025

Metastases • Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor • Triple Negative Breast Cancer

IPG7236 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=196 | Recruiting | Sponsor: Nanjing Immunophage Biotech Co., Ltd | Trial completion date: Mar 2024 ➔ Dec 2024 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Metastases • Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor • Triple Negative Breast Cancer

Discovery of a Potent and Selective CCR8 Small Molecular Antagonist IPG7236 for the Treatment of Cancer. (PubMed, J Med Chem) - "IPG7236 alone or in combination with PD-1 antibody exhibited significant tumor suppression effects in the mouse xenograft model of human breast cancer. IPG7236 is a promising clinical candidate that targets CCR8 with excellent in vitro ADMET properties, pharmacokinetics, safety profiles, and in vivo efficacy."

Journal • Breast Cancer • Oncology • Solid Tumor • CCR8

A Study of Orally Administered IPG7236 in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=86 | Not yet recruiting | Sponsor: Nanjing Immunophage Biotech Co., Ltd

New P1 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology